Literature DB >> 19258595

Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement.

Zhengqi Wang1, Geqiang Li, William Tse, Kevin D Bunting.   

Abstract

Currently, there is a major need in hematopoietic stem cell (HSC) transplantation to develop reduced-intensity regimens that do not cause DNA damage and associated toxicities and that allow a wider range of patients to receive therapy. Cytokine receptor signals through c-Kit and c-Mpl can modulate HSC quiescence and engraftment, but the intracellular signals and transcription factors that mediate these effects during transplantation have not been defined. Here we show that loss of one allele of signal transducer and activator of transcription 5 (STAT5) in nonablated adult mutant mice permitted engraftment with wild-type HSC. Conditional deletion of STAT5 using Mx1-Cre caused maximal reduction in STAT5 mRNA (> 97%) and rapidly decreased quiescence-associated c-Mpl downstream targets (Tie-2, p57), increased HSC cycling, and gradually reduced survival and depleted the long-term HSC pool. Host deletion of STAT5 was persistent and permitted efficient donor long-term HSC engraftment in primary and secondary hosts in the absence of ablative conditioning. Overall, these studies establish proof of principle for targeting of STAT5 as novel transplantation conditioning and demonstrate, for the first time, that STAT5, a mitogenic factor in most cell types, including hematopoietic progenitors, is a key transcriptional regulator that maintains quiescence of HSC during steady-state hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258595      PMCID: PMC2686137          DOI: 10.1182/blood-2008-09-181107

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Orderly process of sequential cytokine stimulation is required for activation and maximal proliferation of primitive human bone marrow CD34+ hematopoietic progenitor cells residing in G0.

Authors:  A C Ladd; R Pyatt; A Gothot; S Rice; J McMahel; C M Traycoff; E F Srour
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  CD45 congenic bone marrow transplantation: evidence for T cell-mediated immunity.

Authors:  Hong Xu; Beate G Exner; Paula M Chilton; Carrie Schanie; Suzanne T Ildstad
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

3.  Lymphohematopoietic engraftment in minimally myeloablated hosts.

Authors:  F M Stewart; S Zhong; J Wuu; C Hsieh; S K Nilsson; P J Quesenberry
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

4.  Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model.

Authors:  S K Nilsson; M S Dooner; C Y Tiarks; H U Weier; P J Quesenberry
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

5.  Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment.

Authors:  S S Rao; S O Peters; R B Crittenden; F M Stewart; H S Ramshaw; P J Quesenberry
Journal:  Exp Hematol       Date:  1997-02       Impact factor: 3.084

6.  A STAT5 modifier locus on murine chromosome 7 modulates engraftment of hematopoietic stem cells during steady-state hematopoiesis.

Authors:  Christine Couldrey; Heath L Bradley; Kevin D Bunting
Journal:  Blood       Date:  2004-10-21       Impact factor: 22.113

7.  Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis.

Authors:  N Takakura; X L Huang; T Naruse; I Hamaguchi; D J Dumont; G D Yancopoulos; T Suda
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

8.  Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Wei Tong
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

9.  Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Authors:  Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

10.  Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.

Authors:  S Teglund; C McKay; E Schuetz; J M van Deursen; D Stravopodis; D Wang; M Brown; S Bodner; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

View more
  58 in total

1.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  An intrinsic BM hematopoietic niche occupancy defect of HSC in scid mice facilitates exogenous HSC engraftment.

Authors:  Yulan Qing; Yuan Lin; Stanton L Gerson
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

Review 3.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

4.  HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency.

Authors:  Jinwei Du; Yu Chen; Qiang Li; Xiangzi Han; Cindy Cheng; Zhengqi Wang; David Danielpour; Sally L Dunwoodie; Kevin D Bunting; Yu-Chung Yang
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

5.  The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B.

Authors:  Akiko Kimura; Cyril Martin; Gertraud W Robinson; James M Simone; Weiping Chen; Mark C Wickre; John J O'Shea; Lothar Hennighausen
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

6.  The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression.

Authors:  Ji Hoon Yu; Bing-Mei Zhu; Mark Wickre; Gregory Riedlinger; Weiping Chen; Atsushi Hosui; Gertraud W Robinson; Lothar Hennighausen
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 7.  Genetic control of quiescence in hematopoietic stem cells.

Authors:  Takeshi Yamada; Chun Shik Park; H Daniel Lacorazza
Journal:  Cell Cycle       Date:  2013-06-28       Impact factor: 4.534

Review 8.  The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Authors:  Michael A Goodman; Punam Malik
Journal:  Ther Adv Hematol       Date:  2016-06-25

9.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Authors:  Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis.

Authors:  Akiko Kimura; Michael A Rieger; James M Simone; Weiping Chen; Mark C Wickre; Bing-Mei Zhu; Philipp S Hoppe; John J O'Shea; Timm Schroeder; Lothar Hennighausen
Journal:  Blood       Date:  2009-09-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.